Last update 16 Aug 2025

HRS-5041

Overview

Basic Info

Drug Type
Proteolysis-targeting chimeras (PROTAC)
Synonyms
HRS 5041, HRS-5041, HRS5041
Target
AR
Action
degraders
Mechanism
AR degraders(Androgen Receptor degraders)
Therapeutic Areas
NeoplasmsUrogenital Diseases
Active Indication
Advanced Prostate CarcinomaMetastatic castration-resistant prostate cancerAdvanced cancer
Inactive Indication-
Originator Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Active Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.Atridia Pty Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

9
Clinical Trials associated with HRS-5041
NCT07115446
/ Not yet recruitingPhase 1
A Phase Ib Study to Explore the Safety, Tolerability, and Pharmacokinetics of HS-20093 Combination With HRS-5041 in Patients With Advanced Prostate Cancer
NCT06830850
/ RecruitingPhase 1
A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
NCT07014488
/ Not yet recruitingPhase 1
A Single-center, Single-arm, Open-label, Fixed-sequence Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects
100 Clinical Results associated with HRS-5041
Login to view more data
100 Translational Medicine associated with HRS-5041
Login to view more data
100 Patents (Medical) associated with HRS-5041
Login to view more data
100 Deals associated with HRS-5041
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Prostate CarcinomaPhase 2
China
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.
06 Sep 2024
Metastatic castration-resistant prostate cancerPhase 1
China
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.
03 Aug 2023
Advanced cancerIND Approval
China
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.
18 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free